Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Influenza Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Vaccines
1.2.3 Drugs
1.3 Market by Application
1.3.1 Global Influenza Therapeutics Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Influenza Therapeutics Market Perspective (2018-2033)
2.2 Influenza Therapeutics Growth Trends by Region
2.2.1 Global Influenza Therapeutics Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Influenza Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Influenza Therapeutics Forecasted Market Size by Region (2024-2033)
2.3 Influenza Therapeutics Market Dynamics
2.3.1 Influenza Therapeutics Industry Trends
2.3.2 Influenza Therapeutics Market Drivers
2.3.3 Influenza Therapeutics Market Challenges
2.3.4 Influenza Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Influenza Therapeutics Players by Revenue
3.1.1 Global Top Influenza Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Influenza Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Influenza Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Influenza Therapeutics Revenue
3.4 Global Influenza Therapeutics Market Concentration Ratio
3.4.1 Global Influenza Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Influenza Therapeutics Revenue in 2022
3.5 Influenza Therapeutics Key Players Head office and Area Served
3.6 Key Players Influenza Therapeutics Product Solution and Service
3.7 Date of Enter into Influenza Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Influenza Therapeutics Breakdown Data by Type
4.1 Global Influenza Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Influenza Therapeutics Forecasted Market Size by Type (2024-2033)
5 Influenza Therapeutics Breakdown Data by Application
5.1 Global Influenza Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Influenza Therapeutics Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Influenza Therapeutics Market Size (2018-2033)
6.2 North America Influenza Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Influenza Therapeutics Market Size by Country (2018-2023)
6.4 North America Influenza Therapeutics Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Influenza Therapeutics Market Size (2018-2033)
7.2 Europe Influenza Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Influenza Therapeutics Market Size by Country (2018-2023)
7.4 Europe Influenza Therapeutics Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Influenza Therapeutics Market Size (2018-2033)
8.2 Asia-Pacific Influenza Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Influenza Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Influenza Therapeutics Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Influenza Therapeutics Market Size (2018-2033)
9.2 Latin America Influenza Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Influenza Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Influenza Therapeutics Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Influenza Therapeutics Market Size (2018-2033)
10.2 Middle East & Africa Influenza Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Influenza Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Influenza Therapeutics Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Influenza Therapeutics Introduction
11.1.4 Abbott Laboratories Revenue in Influenza Therapeutics Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Astrazeneca PLC
11.2.1 Astrazeneca PLC Company Detail
11.2.2 Astrazeneca PLC Business Overview
11.2.3 Astrazeneca PLC Influenza Therapeutics Introduction
11.2.4 Astrazeneca PLC Revenue in Influenza Therapeutics Business (2018-2023)
11.2.5 Astrazeneca PLC Recent Development
11.3 Biocryst Pharmaceuticals, Inc.
11.3.1 Biocryst Pharmaceuticals, Inc. Company Detail
11.3.2 Biocryst Pharmaceuticals, Inc. Business Overview
11.3.3 Biocryst Pharmaceuticals, Inc. Influenza Therapeutics Introduction
11.3.4 Biocryst Pharmaceuticals, Inc. Revenue in Influenza Therapeutics Business (2018-2023)
11.3.5 Biocryst Pharmaceuticals, Inc. Recent Development
11.4 Chiron Corporation
11.4.1 Chiron Corporation Company Detail
11.4.2 Chiron Corporation Business Overview
11.4.3 Chiron Corporation Influenza Therapeutics Introduction
11.4.4 Chiron Corporation Revenue in Influenza Therapeutics Business (2018-2023)
11.4.5 Chiron Corporation Recent Development
11.5 CSL Limited
11.5.1 CSL Limited Company Detail
11.5.2 CSL Limited Business Overview
11.5.3 CSL Limited Influenza Therapeutics Introduction
11.5.4 CSL Limited Revenue in Influenza Therapeutics Business (2018-2023)
11.5.5 CSL Limited Recent Development
11.6 Daiichi Sankyo Co., Ltd.
11.6.1 Daiichi Sankyo Co., Ltd. Company Detail
11.6.2 Daiichi Sankyo Co., Ltd. Business Overview
11.6.3 Daiichi Sankyo Co., Ltd. Influenza Therapeutics Introduction
11.6.4 Daiichi Sankyo Co., Ltd. Revenue in Influenza Therapeutics Business (2018-2023)
11.6.5 Daiichi Sankyo Co., Ltd. Recent Development
11.7 Glaxosmithkline PLC
11.7.1 Glaxosmithkline PLC Company Detail
11.7.2 Glaxosmithkline PLC Business Overview
11.7.3 Glaxosmithkline PLC Influenza Therapeutics Introduction
11.7.4 Glaxosmithkline PLC Revenue in Influenza Therapeutics Business (2018-2023)
11.7.5 Glaxosmithkline PLC Recent Development
11.8 Mitsubishi Tanabe Pharma Corporation
11.8.1 Mitsubishi Tanabe Pharma Corporation Company Detail
11.8.2 Mitsubishi Tanabe Pharma Corporation Business Overview
11.8.3 Mitsubishi Tanabe Pharma Corporation Influenza Therapeutics Introduction
11.8.4 Mitsubishi Tanabe Pharma Corporation Revenue in Influenza Therapeutics Business (2018-2023)
11.8.5 Mitsubishi Tanabe Pharma Corporation Recent Development
11.9 Nanotherapeutics Inc.
11.9.1 Nanotherapeutics Inc. Company Detail
11.9.2 Nanotherapeutics Inc. Business Overview
11.9.3 Nanotherapeutics Inc. Influenza Therapeutics Introduction
11.9.4 Nanotherapeutics Inc. Revenue in Influenza Therapeutics Business (2018-2023)
11.9.5 Nanotherapeutics Inc. Recent Development
11.10 Protein Sciences Corporation
11.10.1 Protein Sciences Corporation Company Detail
11.10.2 Protein Sciences Corporation Business Overview
11.10.3 Protein Sciences Corporation Influenza Therapeutics Introduction
11.10.4 Protein Sciences Corporation Revenue in Influenza Therapeutics Business (2018-2023)
11.10.5 Protein Sciences Corporation Recent Development
11.11 Roche Holding AG
11.11.1 Roche Holding AG Company Detail
11.11.2 Roche Holding AG Business Overview
11.11.3 Roche Holding AG Influenza Therapeutics Introduction
11.11.4 Roche Holding AG Revenue in Influenza Therapeutics Business (2018-2023)
11.11.5 Roche Holding AG Recent Development
11.12 Sanofi SA
11.12.1 Sanofi SA Company Detail
11.12.2 Sanofi SA Business Overview
11.12.3 Sanofi SA Influenza Therapeutics Introduction
11.12.4 Sanofi SA Revenue in Influenza Therapeutics Business (2018-2023)
11.12.5 Sanofi SA Recent Development
11.13 Shionogi & Co., Ltd.
11.13.1 Shionogi & Co., Ltd. Company Detail
11.13.2 Shionogi & Co., Ltd. Business Overview
11.13.3 Shionogi & Co., Ltd. Influenza Therapeutics Introduction
11.13.4 Shionogi & Co., Ltd. Revenue in Influenza Therapeutics Business (2018-2023)
11.13.5 Shionogi & Co., Ltd. Recent Development
11.14 Sinovac Biotech Ltd.
11.14.1 Sinovac Biotech Ltd. Company Detail
11.14.2 Sinovac Biotech Ltd. Business Overview
11.14.3 Sinovac Biotech Ltd. Influenza Therapeutics Introduction
11.14.4 Sinovac Biotech Ltd. Revenue in Influenza Therapeutics Business (2018-2023)
11.14.5 Sinovac Biotech Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Influenza Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Vaccines
Table 3. Key Players of Drugs
Table 4. Global Influenza Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Influenza Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Influenza Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Influenza Therapeutics Market Share by Region (2018-2023)
Table 8. Global Influenza Therapeutics Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Influenza Therapeutics Market Share by Region (2024-2033)
Table 10. Influenza Therapeutics Market Trends
Table 11. Influenza Therapeutics Market Drivers
Table 12. Influenza Therapeutics Market Challenges
Table 13. Influenza Therapeutics Market Restraints
Table 14. Global Influenza Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Influenza Therapeutics Market Share by Players (2018-2023)
Table 16. Global Top Influenza Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Therapeutics as of 2022)
Table 17. Ranking of Global Top Influenza Therapeutics Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Influenza Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Influenza Therapeutics Product Solution and Service
Table 21. Date of Enter into Influenza Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Influenza Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Influenza Therapeutics Revenue Market Share by Type (2018-2023)
Table 25. Global Influenza Therapeutics Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Influenza Therapeutics Revenue Market Share by Type (2024-2033)
Table 27. Global Influenza Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Influenza Therapeutics Revenue Market Share by Application (2018-2023)
Table 29. Global Influenza Therapeutics Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Influenza Therapeutics Revenue Market Share by Application (2024-2033)
Table 31. North America Influenza Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Influenza Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Influenza Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Influenza Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Influenza Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Influenza Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Influenza Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Influenza Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Influenza Therapeutics Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Influenza Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Influenza Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Influenza Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Influenza Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Influenza Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Influenza Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 46. Abbott Laboratories Company Detail
Table 47. Abbott Laboratories Business Overview
Table 48. Abbott Laboratories Influenza Therapeutics Product
Table 49. Abbott Laboratories Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 50. Abbott Laboratories Recent Development
Table 51. Astrazeneca PLC Company Detail
Table 52. Astrazeneca PLC Business Overview
Table 53. Astrazeneca PLC Influenza Therapeutics Product
Table 54. Astrazeneca PLC Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 55. Astrazeneca PLC Recent Development
Table 56. Biocryst Pharmaceuticals, Inc. Company Detail
Table 57. Biocryst Pharmaceuticals, Inc. Business Overview
Table 58. Biocryst Pharmaceuticals, Inc. Influenza Therapeutics Product
Table 59. Biocryst Pharmaceuticals, Inc. Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 60. Biocryst Pharmaceuticals, Inc. Recent Development
Table 61. Chiron Corporation Company Detail
Table 62. Chiron Corporation Business Overview
Table 63. Chiron Corporation Influenza Therapeutics Product
Table 64. Chiron Corporation Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 65. Chiron Corporation Recent Development
Table 66. CSL Limited Company Detail
Table 67. CSL Limited Business Overview
Table 68. CSL Limited Influenza Therapeutics Product
Table 69. CSL Limited Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 70. CSL Limited Recent Development
Table 71. Daiichi Sankyo Co., Ltd. Company Detail
Table 72. Daiichi Sankyo Co., Ltd. Business Overview
Table 73. Daiichi Sankyo Co., Ltd. Influenza Therapeutics Product
Table 74. Daiichi Sankyo Co., Ltd. Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 75. Daiichi Sankyo Co., Ltd. Recent Development
Table 76. Glaxosmithkline PLC Company Detail
Table 77. Glaxosmithkline PLC Business Overview
Table 78. Glaxosmithkline PLC Influenza Therapeutics Product
Table 79. Glaxosmithkline PLC Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 80. Glaxosmithkline PLC Recent Development
Table 81. Mitsubishi Tanabe Pharma Corporation Company Detail
Table 82. Mitsubishi Tanabe Pharma Corporation Business Overview
Table 83. Mitsubishi Tanabe Pharma Corporation Influenza Therapeutics Product
Table 84. Mitsubishi Tanabe Pharma Corporation Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 85. Mitsubishi Tanabe Pharma Corporation Recent Development
Table 86. Nanotherapeutics Inc. Company Detail
Table 87. Nanotherapeutics Inc. Business Overview
Table 88. Nanotherapeutics Inc. Influenza Therapeutics Product
Table 89. Nanotherapeutics Inc. Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 90. Nanotherapeutics Inc. Recent Development
Table 91. Protein Sciences Corporation Company Detail
Table 92. Protein Sciences Corporation Business Overview
Table 93. Protein Sciences Corporation Influenza Therapeutics Product
Table 94. Protein Sciences Corporation Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 95. Protein Sciences Corporation Recent Development
Table 96. Roche Holding AG Company Detail
Table 97. Roche Holding AG Business Overview
Table 98. Roche Holding AG Influenza Therapeutics Product
Table 99. Roche Holding AG Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 100. Roche Holding AG Recent Development
Table 101. Sanofi SA Company Detail
Table 102. Sanofi SA Business Overview
Table 103. Sanofi SA Influenza Therapeutics Product
Table 104. Sanofi SA Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 105. Sanofi SA Recent Development
Table 106. Shionogi & Co., Ltd. Company Detail
Table 107. Shionogi & Co., Ltd. Business Overview
Table 108. Shionogi & Co., Ltd. Influenza Therapeutics Product
Table 109. Shionogi & Co., Ltd. Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 110. Shionogi & Co., Ltd. Recent Development
Table 111. Sinovac Biotech Ltd. Company Detail
Table 112. Sinovac Biotech Ltd. Business Overview
Table 113. Sinovac Biotech Ltd. Influenza Therapeutics Product
Table 114. Sinovac Biotech Ltd. Revenue in Influenza Therapeutics Business (2018-2023) & (US$ Million)
Table 115. Sinovac Biotech Ltd. Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Influenza Therapeutics Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Influenza Therapeutics Market Share by Type: 2022 VS 2033
Figure 3. Vaccines Features
Figure 4. Drugs Features
Figure 5. Global Influenza Therapeutics Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Influenza Therapeutics Market Share by Application: 2022 VS 2033
Figure 7. Hospitals Case Studies
Figure 8. Clinic Case Studies
Figure 9. Others Case Studies
Figure 10. Influenza Therapeutics Report Years Considered
Figure 11. Global Influenza Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Influenza Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Influenza Therapeutics Market Share by Region: 2022 VS 2033
Figure 14. Global Influenza Therapeutics Market Share by Players in 2022
Figure 15. Global Top Influenza Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Therapeutics as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Influenza Therapeutics Revenue in 2022
Figure 17. North America Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Influenza Therapeutics Market Share by Country (2018-2033)
Figure 19. United States Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Influenza Therapeutics Market Share by Country (2018-2033)
Figure 23. Germany Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Influenza Therapeutics Market Share by Region (2018-2033)
Figure 31. China Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Influenza Therapeutics Market Share by Country (2018-2033)
Figure 39. Mexico Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Influenza Therapeutics Market Share by Country (2018-2033)
Figure 43. Turkey Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia Influenza Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Abbott Laboratories Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 46. Astrazeneca PLC Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 47. Biocryst Pharmaceuticals, Inc. Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 48. Chiron Corporation Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 49. CSL Limited Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 50. Daiichi Sankyo Co., Ltd. Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 51. Glaxosmithkline PLC Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 52. Mitsubishi Tanabe Pharma Corporation Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 53. Nanotherapeutics Inc. Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 54. Protein Sciences Corporation Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 55. Roche Holding AG Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 56. Sanofi SA Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 57. Shionogi & Co., Ltd. Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 58. Sinovac Biotech Ltd. Revenue Growth Rate in Influenza Therapeutics Business (2018-2023)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed